Shaikh Taha Gul, Waseem Summaiyya, Ahmed Syed Hassan, Qadir Nashwa Abdul, Piccolo Vincenzo
Dow University of Health Sciences, Karachi, Pakistan.
Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy.
Dermatol Pract Concept. 2022 Oct 1;12(4):e2022170. doi: 10.5826/dpc.1204a170. eCollection 2022 Nov.
The coronavirus pandemic has caused massive damage to global health care and the economy. The vaccination program has been paced around the globe to return as soon as possible to pre-COVID time. Although all the vaccines have been approved after the rigorous clinical and safety trials, some adverse effects have surfaced and are being reported from different parts of the world. One such side effect is chilblain-like lesions following the COVID vaccination. Chilblain lesions, also known as pernio, are an inflammatory condition usually affecting the acral regions of the body. It is mostly reported from cold and damp areas and has multiple causes associated with it.
This study aims to review the publicly available data and to provide concise and comprehensive information as well as evaluate the potential pathology, clinical approach, and management of CLL post-vaccination.
An extensive literature search over PubMed, Cochrane library, Google Scholar, and Clinicaltrails. gov from inception till 5th October 2021, without any restriction of language was carried out. All the recruited articles were reviewed, and their bibliographies were also screened for any relevant information.
12 studies (10 case reports and 2 case series) were retrieved reporting the incidence of CLL post-vaccination. 8 studies reported incidence in female patients while 5 reported in males, with one study mentioning no gender. Moreover, most of them were either from Europe or the United States of America, except for two cases, reported from Turkey.
Although the overall incidence of Chilblains following COVID-19 vaccination is low, there is still a strong need to find out the exact mechanism behind this to redefine the safety and administration criteria of the vaccines and to formulate a proper management protocol.
新冠疫情对全球医疗保健和经济造成了巨大破坏。全球范围内的疫苗接种计划正在稳步推进，以期尽快恢复到新冠疫情前的状态。尽管所有疫苗都经过了严格的临床和安全性试验才获得批准，但一些不良反应已经出现，并在世界不同地区得到报告。其中一种副作用就是接种新冠疫苗后出现冻疮样病变。冻疮样病变，也称为冻疮，是一种通常影响身体肢端部位的炎症性疾病。大多在寒冷潮湿地区有报告，且与之相关的病因有多种。
本研究旨在回顾公开可用的数据，提供简明全面的信息，并评估接种疫苗后冻疮样病变的潜在病理、临床方法及管理。
从创刊至2021年10月5日，在PubMed、Cochrane图书馆、谷歌学术和Clinicaltrails.gov上进行了广泛的文献检索，没有语言限制。对所有纳入的文章进行了综述，并对其参考文献也进行了筛选以获取任何相关信息。
检索到12项研究（10例病例报告和2例病例系列）报告了接种疫苗后冻疮样病变的发生率。8项研究报告了女性患者的发生率，5项报告了男性患者的发生率，有1项研究未提及性别。此外，除了2例报告来自土耳其的病例外，大多数研究来自欧洲或美国。
尽管新冠疫苗接种后冻疮的总体发生率较低，但仍迫切需要找出其背后的确切机制，以重新定义疫苗的安全性和接种标准，并制定适当的管理方案。
